Research Article

Leishmania infantum FML pulsed-dendritic cells induce a protective immune response in murine visceral leishmaniasis

Departmant of Parasitology & Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

Departmant of Parasitology & Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Basic Science in Infectious Diseases Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

^‡Authors contributed equally

Search for more papers by this author

Bahador Sarkari

Departmant of Parasitology & Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Search for more papers by this author

Eskandar Kamali-Sarvestani^,‡

*Author for correspondence:

E-mail Address: immunol2@sums.ac.ir

Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Autoimmune Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Proteomics Laboratory, School of Advanced Medical Sciences & Technologies, Shiraz, Iran

^‡Authors contributed equally

Search for more papers by this author

Published Online:9 Jan 2015https://doi.org/10.2217/imt.14.102

View article

Abstract

Aim: To investigate the efficacy of FML loaded dendritic cells (DCs) in protection against visceral leishmaniasis. Materials & methods: Mice were immunized with FML- or soluble Leishmania antigen-loaded DCs as well as FML or soluble Leishmania antigen in saponin and challenged with parasite. The levels of cytokines before and after challenge were detected by ELISA. Parasite burden (total Leishman–Donovan unit) was determined after parasite challenge. Results: FML-saponin induced the highest IFN-γ/IL-4 ratio among vaccinated groups, though this ratio was higher in FML-loaded DCs group subsequent to challenge with Leishmania infantum. Moreover, the greatest reduction in parasite number was detected in mice vaccinated with FML-loaded DCs compared with phosphate-buffered saline-treated mice (p = 0.002). Conclusion: FML-loaded DCs are one of the promising tools for protection against murine visceral leishmaniasis.

Keywords:

References

1 Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans. R. Soc. Trop. Med. Hyg. 95, 239–243 (2001).Crossref, Medline, CAS, Google Scholar
2 Khalil EA, El Hassan AM, Zijlstra EE et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 356, 1565–1569 (2000).Crossref, Medline, CAS, Google Scholar
3 Musa AM, Khalil EA, Mahgoub FA et al. Leishmaniasis Research Group/Sudan. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans. R. Soc. Trop. Med. Hyg. 102, 58–63 (2008).Crossref, Medline, CAS, Google Scholar
4 Bhaumik SK, Naskar K, De T. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1‐immunity and down‐regulation of IL‐10. Eur. J. Immunol. 39, 2146–2160 (2009).Crossref, Medline, CAS, Google Scholar
5 Aguilar-Be I, da Silva Zardo R, Paraguai de Souza E et al. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect. Immun. 73, 812–819 (2005).Crossref, Medline, CAS, Google Scholar
6 Parody N, Soto M, Requena JM, Alonso C. Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG+ Q mix protects Balb/c mice from infection. Parasite Immunol. 26, 283–293 (2004).Crossref, Medline, CAS, Google Scholar
7 Wilson ME, Young BM, Andersen KP et al. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice. Infect. Immun. 63, 2062–2069 (1995).Crossref, Medline, CAS, Google Scholar
8 Santos WR, Aguiar IA, Paraguai de Souza E, de Lima VM, Palatnik M, Palatnik-de-Sousa CB. Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine. Vaccine 21, 4668–4676 (2003).Crossref, Medline, CAS, Google Scholar
9 Palatnik-de-Sousa CB, Silva-Antunes I, Morgado Ade A, Menz I, Palatnik M, Lavor C. Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas. Vaccine 27, 3505–3512 (2009).Crossref, Medline, Google Scholar
10 Borja-Cabrera GP, Cruz Mendes A, Paraguai de Souza E et al. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 22, 2234–2243 (2004).Crossref, Medline, CAS, Google Scholar
11 de Lima VM, Ikeda FA, Rossi CN et al. Diminished CD4+/CD25+ T cell and increased IFN-gamma levels occur in dogs vaccinated with Leishmune in an endemic area for visceral leishmaniasis. Vet. Immunol. Immunopathol. 135, 296–302 (2010).Crossref, Medline, CAS, Google Scholar
12 Palatnik-de-Sousa CB, Paraguai-de-Souza E, Gomes EM, Borojevic R. Experimental murine Leishmania donovani infection: immunoprotection by the fucose-mannose ligand (FML). Braz. J. Med. Biol. Res. 27, 547–551 (1994).Medline, CAS, Google Scholar
13 Santos WR, de Lima VM, de Souza EP, Bernardo RR, Palatnik M, Palatnik de Sousa CB. Saponins, IL-12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 21, 30–43 (2002).Crossref, Medline, CAS, Google Scholar
14 Matos I, Mizenina O, Lubkin A, Steinman RM, Idoyaga J. Targeting Leishmania major antigens to dendritic cells in vivo induces protective immunity. PLoS ONE 8, e67453 (2013).Crossref, Medline, CAS, Google Scholar
15 Remer KA, Apetrei C, Schwarz T, Linden C, Moll H. Vaccination with plasmacytoid dendritic cells induces protection against infection with Leishmania major in mice. Eur. J. Immunol. 37, 2463–2473 (2007).Crossref, Medline, CAS, Google Scholar
16 Ahuja SS, Reddick RL, Sato N et al. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J. Immunol. 163, 3890–3897 (1999).Medline, CAS, Google Scholar
17 Ghosh M, Pal C, Ray M, Maitra S, Mandal L, Bandyopadhyay S. Dendritic cell-based immunotherapy combined with antimony-based chemotherapy cures established murine visceral leishmaniasis. J. Immunol. 170, 5625–5629 (2003).Crossref, Medline, CAS, Google Scholar
18 Stauber L. Leishmaniasis in the hamster. In: Some Physiological Aspects and Consequences of Parasitism. Cole WH (Ed.). Rutgers University Press, New Brunswisck, NJ, USA, 76–90 (1955).Google Scholar
19 Tsagozis P, Karagouni E, Dotsika E. Dendritic cells pulsed with peptides of gp63 induce differential protection against experimental cutaneous leishmaniasis. Int. J. Immunopathol. Pharmacol. 17, 343–352 (2004).Crossref, Medline, CAS, Google Scholar
20 Agallou M, Smirlis D, Soteriadou KP, Karagouni E. Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis. Vaccine 30, 5086–5093 (2012).Crossref, Medline, CAS, Google Scholar
21 Carrión J, Folgueira C, Alonso C. Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells. Vaccine 26, 2537–2544 (2008).Crossref, Medline, CAS, Google Scholar
22 Agallou M, Margaroni M, Karagouni E. Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis. Vaccine 29, 5053–5064 (2011).Crossref, Medline, CAS, Google Scholar
23 Nico D, Claser C, Borja-Cabrera GP et al. Adaptive immunity against leishmania nucleoside hydrolase maps its C-terminal domain as the target of the CD4+ T cell-driven protective response. PLoS Negl. Trop. Dis. 4, 1–13 (2010).Crossref, Google Scholar
24 Sun H-X, Xie Y, Ye Y-P. Advances in saponin-based adjuvants. Vaccine 27, 1787–1796 (2009).Crossref, Medline, CAS, Google Scholar
25 Oliveira-Freitas E1, Casas CP, Borja-Cabrera GP et al. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis. Vaccine 24, 3909–3920 (2006).Crossref, Medline, CAS, Google Scholar
26 Stern JJ, Oca MJ, Rubin BY, Anderson SL, Murray HW. Role of L3T4+ and Lyt-2+ cells in experimental visceral leishmaniasis. J. Immunol. 140, 3971–3977 (1988).Medline, CAS, Google Scholar
27 Stanley AC, Engwerda CR. Balancing immunity and pathology in visceral leishmaniasis. Immunol. Cell. Biol. 85, 138–147 (2007).Crossref, Medline, CAS, Google Scholar
28 Majumder S, Bhattacharjee A, Paul Chowdhury B, Bhattacharyya Majumdar S, Majumdar S. Antigen-pulsed CpG-ODN-activated dendritic cells induce host-protective immune response by regulating the T regulatory cell functioning in Leishmania donovani-infected mice: critical role of CXCL10. Front. Immunol. 5, 261 (2014).Crossref, Medline, Google Scholar

Vol. 7, No. 1

Metrics

Downloaded 40 times

History

Published online 9 January 2015

Published in print January 2015

Information

Keywords

Acknowledgements

This article is derived from the PhD thesis of F Foroughi-Parvar at Shiraz University of Medical Sciences, School of Medicine. The authors would like to thank F Taki from autoimmune diseases research center and P Habibi for their technical assistance.

Financial & competing interests disclosure

The study was financially supported by the office of vice-chancellor for research of Shiraz University of Medical Sciences (grant number 91-5800). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download